News

Naturex reports "steady" revenue in first quarter

19 May 2017

Naturex has reported that 2017 first quarter revenue amounted to €104.4 million, in line with the same period in 2016, including a positive currency effect. Recurring operational EBITDA on that basis came to €15.8 million, representing a margin of 15.1%.

Naturex reports steady revenue in first quarter

Naturex has reported that 2017 first quarter revenue amounted to €104.4 million, in line with the same period in 2016, including a positive currency effect. Recurring operational EBITDA on that basis came to €15.8 million, representing a margin of 15.1%.

“As announced when the 2016 annual results were published, 2017 first quarter revenue remained steady in relation to last year's same period,” said CEO Olivier Rigaud. “In accordance with our implementation plan, we concentrated on optimising our product mix by shifting its focus to our four strategic categories, while initiating the final phase in reducing the number of SKUs and accelerating the adoption of simplification measures.”

“Geographically, our regional organisation enabled us to target and adapt our approach to the diverse characteristics and volatility of our markets. In this way, we continued to benefit from opportunities provided by dynamic emerging countries whereas our strong position in North America confirmed our capacity for getting back on track for growth, particularly in the nutraceutical sector. In Europe, comparison base effects and the accelerating rationalisation in the number of SKUs masked the positive effects from certain product categories.”

“Finally, our teams' ongoing efforts to reduce operating expenses and increase operating efficiencies have bolstered our current operating margin.”

As we begin 2017 with confidence, our priorities in the first half are clearly focused on accelerating the simplification measures and in the second half on top line growth and operating profitability," concluded Rigaud.